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Abstract: Tuberculosis is an ancient human disease that is still a major cause of death and one 
of the most challenging public health problems worldwide. After decades of stagnancy, new 
public–private partnerships to fight the disease and the increasing awareness of a vicious circle 
between the tuberculosis epidemic and the obstruction of economic development have fuelled 
recent progress in our understanding of the disease. As a result, new strategies to improve 
management and treatment of tuberculosis have been initiated. At the same time, however, 
the devastating effect of human immunodeficiency virus on tuberculosis susceptibility and the 
rapid expansion of multidrug-resistant (MDR) tuberculosis threaten to undermine the advances 
made by tuberculosis management programs. With an estimated 9 million new cases annually, 
tuberculosis affects a higher number of individuals worldwide than ever before. Here, recent 
developments in the epidemiology and management of tuberculosis are summarized and an 
overview is provided of emerging strategies to combat this ancient scourge.
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Introduction
Tuberculosis is the cause of almost 2 million deaths per year. Two billion   individuals, 
about one-third of the total human population, are infected with the causative 
agent of tuberculosis, Mycobacterium tuberculosis.1 The great majority of infected 
  individuals, however, are latently infected – that is, the pathogen persists in them 
in its dormant form. In Western countries, the disease is mostly held in check by 
efficient health care systems. In many regions of the developing world, however, 
the number of infected individuals often exceeds the capacities to provide sufficient 
prevention and treatment of the disease. Until the end of the last century, the rapid 
increase in   tuberculosis prevalence in these countries was linked to a deterioration in 
socioeconomic development.
With the United Nations Millennium Development Goals and the Stop   Tuberculosis 
Partnership, the World Health Organization (WHO) defined the strategy for the years 
to 2015 and 2050, respectively.2,3 The Millennium Development Goals include the 
halt of disease spread, efforts to reduce the incidence of disease, the reduction of 
death rates, as well as the improvement of detection and cure. By 2050, the aim is to 
eliminate the disease by reducing the global incidence to below one tuberculosis case 
per million individuals per year.4,5
In this review, the current state of tuberculosis diagnostics and treatment, new 
  challenges in tuberculosis control, and some of the novel approaches that are underway 
to improve current methods for disease control are discussed.
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Epidemiology: past, present  
and future
Tuberculosis is an ancient human disease that can be 
traced back to Egyptian mummies. Until the beginning 
of the 1990s, tuberculosis was considered a disease under 
control with decreasing political and industrial interest. 
Since then, both the development of multidrug resistant 
(MDR) strains and the increasing problem of co-infection 
with human   immunodeficiency virus (HIV), have led to a 
new   exacerbation of disease spread that has restrengthened 
the urge to develop new strategies and drugs. To date, the 
estimated tuberculosis incidence has risen to 8.8 million 
worldwide.6 While in Western Europe the tuberculosis 
burden has decreased in recent years, the disease has spread 
with the growing global population, especially in Asia and 
Africa, with a 2.7% mean annual increase between 2004 and 
2008.7 Eighty percent of all tuberculosis cases occur in India, 
China, South Africa, Nigeria, and Indonesia.6
Recent developments
So far, all attempts to limit the global tuberculosis burden 
have been counteracted by two major obstacles. First, the 
continuous increase in cases of MDR tuberculosis, which 
will be one of the most difficult challenges to overcome in 
the future. By definition, MDR tuberculosis strains are at least 
resistant to both rifampicin and isoniazid, two commonly used 
antituberculosis drugs.8 The proportion of MDR tuberculosis 
cases is growing, especially in Eastern Europe. This presents 
a serious threat to the low-incidence in Western countries. In 
2008, 440,000 cases of MDR tuberculosis were reported to the 
WHO.4 Of these, only a small percentage had been previously 
treated for tuberculosis – that is, most of the cases result from 
primary transfer of multidrug-resistant strains. The use of 
monotherapeutic agents like isoniazid in many cases leads to 
selection of resistant mutants, which have previously acquired 
resistance to multiple other tuberculosis drugs.9,10 In addition to 
MDR strains, there has been a recent increase in the number of 
cases caused by strains that are extensively resistant (ie, resistant 
to ﬂuoroquinolone and one aminoglycoside) or even resistant 
to all currently available antituberculosis drugs.11 Already 
about 5% of all new tuberculosis cases are due to MDR strains, 
with more than half of all MDR cases occurring in China and 
India. In the Russian Federation, MDR tuberculosis is found 
in 25% of all newly diagnosed patients. It is estimated that 
there are at least 50,000 cases of extensively drug-resistant 
tuberculosis, with a total of 58 countries reporting such cases 
to the WHO.12 This dramatic increase establishes the need 
for efficient diagnosis of drug resistance in newly diagnosed 
tuberculosis cases. However, the lack of reliable phenotypical 
and genotypical characterization methods in countries with high 
MDR burden limits a definitive approach and emphasizes the 
use of aggressive first-line therapy.
Secondly, the exploding number of HIV-associated tuber-
culosis infections has contributed to the continuous increase 
of tuberculosis cases over the last few years. Almost one 
in seven global tuberculosis cases is associated with HIV , 
and about 80% of these are found in sub-Saharan Africa.1 
However, only 34% of tuberculosis patients are tested for 
HIV worldwide.6 Over the last few decades, the risk factors 
associated with tuberculosis susceptibility have changed 
  dramatically. While malnutrition and poverty are still strongly 
associated with the risk of infection with tuberculosis in 
developing countries, HIV has gained a central role among 
risk factors, and the threat of developing active tuberculosis 
is more than 20 times greater in HIV-infected people.13
Smoking is also associated not only with the risk 
of infection (up to 70% increase) but also with disease 
progression (up to 50% increase).14 Furthermore, diabetes 
mellitus has been reported to enhance the risk for developing 
active tuberculosis by about three times.15 Although 
tuberculosis treatment in Europe at the beginning of the 
twentieth century consisted of phototherapy in areas with 
high sun exposure, it was not until 1985 that the connection 
between vitamin D deficiency and tuberculosis was 
identified.16 Research on the underlying cellular mechanism 
finally suggested that cathelicidin, an antimicrobial peptide 
regulated by vitamin D, is a key player in host defense against 
tuberculosis.17 Recently, genetic variants in the vitamin D 
receptor have also been linked to disease susceptibility.17
Furthermore, a risk factor that nowadays plays a critical 
role, especially in Western countries, is immunosuppression 
due to malignancy or immunosuppressive drugs. Treatment 
with tumor-necrosis-factor antagonists in patients suffering 
from rheumatoid diseases has emerged as a central problem 
leading to reactivation of dormant tuberculosis.18
Current management approaches 
and challenges
Current management approaches concentrate on three 
  different areas: (1) detection of infected individuals; 
(2) control of patient migration and disease spread; and 
(3) individual treatment, with a focus on drug resistance.
Identification of infected individuals
From an epidemiological point of view, migration is one of 
the factors that drives the spread of tuberculosis. Not only 
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does migration from high- to low-burden countries lead to 
increased disease incidence, it is also the main causative 
factor in the spread of MDR tuberculosis, for instance, from 
Eastern to Western Europe. While the most effective way 
to control tuberculosis is by reducing the tuberculosis cases 
in the countries of origin, many low-incidence countries 
have initiated tuberculosis screening for immigrants. These 
screening programs, however, are far from standardized. 
While some European countries screen for tuberculosis with 
chest X-ray, others use the tuberculin skin test, sometimes 
supplemented by interferon (IFN)-γ assays.19
A major obstacle to global tuberculosis control is the lack 
of reliable biomarkers for different stages of tuberculosis 
infection. According to current WHO guidelines, cultural 
verification of the bacteria remains the diagnostic gold 
  standard.20 However, culture of the causative agent of tuber-
culosis can take up to 6 weeks and requires specific laboratory 
equipment. This makes initial therapeutic approaches diffi-
cult, since infected individuals who have not unequivocally 
been diagnosed continue to spread the disease. Therefore, 
sputum smear analysis is recommended. According to new 
WHO guidelines, only one positive smear result (instead of 
two) suffices to define a tuberculosis case. One has to keep 
in mind, however, that the diagnostic conclusiveness of 
microscopy approaches is quite dependent on the experience 
of the microscopist, with sensitivity ranging between 32% 
and 97%.21,22 For several decades, the standard screening 
test for infection with M. tuberculosis was the tuberculin 
skin test. In the case of a positive test result, the delayed 
hypersensitivity response can be observed up to 72 hours after 
intradermal injection of tuberculin. Downsides of this test are 
the lack of specificity for M. tuberculosis and the high rate 
of false-positive results in people who have received Bacille 
Calmette-Guérin (BCG) vaccination as well as in children or 
immunosuppressed patients.23 IFN-γ-release assays are used 
to eliminate these caveats. Over the last 10–15 years, new 
immunological tests have been developed that are now widely 
used in clinical   practice. Both use IFN-γ secretion from T cells 
as a specific marker of tuberculosis infection. In contrast to 
the tuberculin skin test, they use specific protein antigens 
from M.   tuberculosis, thus avoiding false-positive results after 
BCG vaccination. In these tests, either single IFN-γ-secreting 
T cells are counted using an enzyme-linked immunospot 
technique-based approach, or IFN-γ secretion is measured in 
a blood sample via enzyme-linked immunosorbent assay after 
antigen stimulation. These approaches have a high sensitivity 
(up to 90%) for individuals with latent tuberculosis infection 
as well as patients with active disease.24,25
The tests described require much less time but are also not 
as stringent as the gold standard for tuberculosis diagnosis, 
which is the culture of M. tuberculosis from patient samples. 
As previously mentioned, culture of the causative agent of 
tuberculosis is a lengthy procedure, so IFN-γ tests provide 
a substantial improvement in early diagnosis for both latent 
infection and active disease. Thus, these methods might 
help identify early sources of infection and help limit 
disease spread, provided that they become broadly and 
cost-effectively available in high-burden countries.23
Current treatment options
Once identified, patients suffering from tuberculosis must 
undergo immediate treatment. The current WHO guide-
lines are based on the internationally agreed strategy for 
tuberculosis control (the Directly Observed Treatment Short 
course [DOTS]).26 The recommendations in this program 
include not only standardized treatment and patient care but 
also effective disease management and drug supply.26 The 
regime currently recommended consists of isoniazid, rifam-
picin, pyrazinamide, and ethambutol for 2 months. Subse-
quently, patients with newly detected pulmonary tuberculosis 
receive isoniazid and rifampicin for another 2 months. For an 
optimal outcome, the treatment should be given daily.20
If a person has previously undergone tuberculosis 
treatment, drug susceptibility testing is advised, at least for 
isoniazid and rifampicin. As the treatment of drug-resistant 
tuberculosis has recently been summarized,27 treatment 
options in the case of MDR tuberculosis are only brieﬂy 
outlined here and, instead, focus is on the recently emerg-
ing challenge of treating tuberculosis patients with HIV 
co-infection. General WHO recommendations for MDR 
tuberculosis include 2 months of isoniazid, rifampicin, 
pyridazinamide, ethambutol, and streptomycin, followed 
by 1 month without streptomycin and continuous use of 
isoniazid, rifampicin, and ethambutol for 5 more months.20 
Nonetheless, the new WHO guidelines strongly recommend 
drug susceptibility testing whenever possible due to ris-
ing multidrug resistance and the likelihood of nonoptimal 
drugs in the regimen. During the therapy, monthly smears 
and cultures should be analyzed to monitor conversion. 
The treatment should be continued in the case of MDR 
tuberculosis for at least 18 months after culture conversion 
to ensure stable therapy success, which is achieved in about 
65% of patients. Although not yet sufficiently corroborated 
by empirical data, experts suggest ethambutol, pyrazinamide, 
a ﬂuoroquinolone, and an intravenous drug like capreomycin 
for MDR-tuberculosis treatment.28,29 The optimal duration of 
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treatment needs to be evaluated in further studies. Although 
several other drugs have been shown to be effective in the 
treatment of MDR tuberculosis, severe side effects limit 
their use as safe long-term treatment, as is exemplarily dem-
onstrated by linezolid.30 Apart from the requested sputum 
culture conversation, severe side effects like peripheral or 
optic neuropathy occurred in a substantial number of patients 
in a relatively short period of treatment time. For extensively 
drug-resistant tuberculosis, the available data is even more 
limited, emphasizing the need for new drugs.
Treatment of HIv/tuberculosis  
co-infection
A special situation applies to tuberculosis patients who are 
co-infected with HIV . This combination is the major reason 
for the rising prevalence of tuberculosis in sub-Saharan 
Africa. The risk for tuberculosis infection is increased from 
the start of HIV infection and is especially enhanced with a 
CD4+ T cell count of ,500/µL.31,32 In individuals co-infected 
with HIV and tuberculosis, treatment with highly active 
antiretroviral therapy (HAART) plus the above-mentioned 
state-of-the-art tuberculosis treatment is desirable. Currently, 
however, several drug–drug interactions might lead to further 
complications in patients who are simultaneously treated for 
both diseases. Specifically, the use of protease inhibitors is 
often limited when given in combination with rifampicin. In 
this case, rifabutin is preferred.33 Several different measures 
are taken to reduce the number of HIV/tuberculosis co-
infected patients. First, the routine HIV testing is increasingly 
implemented to identify those with HIV , especially in areas 
with high tuberculosis incidence. Second, the WHO now 
recommends prophylaxis with cotrimoxazole, which has 
proven beneficial in patients with and without tuberculosis 
with respect to mortality and CD4+ T cell counts.34 In addi-
tion, early and rigorous treatment of HIV in newly diagnosed 
individuals is strongly indicated, as the risk of tuberculosis 
infection is decreased under HAART, and mortality is 
reduced by up to 95% in infected patients.35,36 This is further 
underlined by the finding that mortality increases by up to 
56% if antiretroviral therapy is delayed until after successful 
treatment of tuberculosis.37
An unsolved problem is the large number of cases with 
confirmed HIV and suspected tuberculosis. Here again, 
more intensive screening would lead to beneficial individual 
treatment and reduced transfer. Another limiting factor for 
combined tuberculosis/HIV treatment can be the develop-
ment of an immune reconstitution inﬂammatory syndrome, 
which is seen in patients with preexisting tuberculosis that 
show clinical worsening after initiation of HAART.38 The 
combined therapy, therefore, should be monitored by experts 
in both fields. When combined with multidrug-resistant 
or extensively drug-resistant tuberculosis, the outcome is 
dramatically worsened and the need for a new therapy even 
greater.9
With respect to morbidity and mortality in co-infected 
individuals, prevention of co-infection is an important aim. 
Isoniazid is recommended for prevention and latent tuber-
culosis infection, as it reduces the risk of tuberculosis in 
HIV-infected people by one-third.39
Emerging strategies to combat 
tuberculosis: current chances  
and challenges
As outlined, the epidemic of multidrug-resistant tuberculosis 
threatens to undermine the success that has been achieved 
with available treatment.40 Currently existing technologies 
can only partly counter this problem. In addition, three 
novel avenues have to be pursued to combat the increasing 
problem of multidrug resistance. First, new diagnostic tests 
are urgently needed for drug-resistant and drug-susceptible 
tuberculosis. Laboratory expertise must be expanded in 
a cost-effective manner and reliable biomarkers for the 
diagnosis of the state of the infection need to be made 
available.41 Second, new antituberculosis drugs are being 
developed, many of which might prove effective against 
existing drug-resistant tuberculosis strains.42 Third, the intro-
duction of a new effective vaccine could be a breakthrough 
in tuberculosis control.43 Effective prevention is the ultimate 
goal on which all currently emerging strategies to combat 
tuberculosis need to converge.
Some of the recent approaches to the design of new anti-
tuberculosis drugs and vaccines will now be summarized, 
the basic mechanisms underlying their function will be 
explained, and a brief overview of the status or the develop-
ment and testing of these substances will be given.
Drug development
Currently available drugs for tuberculosis are insufficient 
to challenge the emerging problems of treatment, and the 
development of new drugs has become a major priority in the 
global effort to reduce worldwide tuberculosis burden. Over 
the last decade, several new drugs have entered the clinical 
pipeline, the most promising of which are summarized in 
Table 1.
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Generally, new antituberculosis drug candidates need to 
have certain characteristics to be successful.44 First, it is highly 
desirable to shorten the treatment of infected patients, and to 
treat latently infected individuals. Thus, new drugs need to show 
efficacy against both dormant and replicating M. tuberculosis. 
Furthermore, as substances active against MDR tuberculosis are 
urgently needed, the molecular mechanisms of action must be 
novel, hence, new drug candidates must have target structures 
that are not directly attacked by currently available antibiotics. 
Second, new drug candidates must be safe. This is especially 
important since children and pregnant women are population 
groups which are highly affected by tuberculosis in some 
countries.45 Therefore, new drugs will only prove efficient if 
their tolerability profile includes these two important population 
groups. Third, a necessary attribute of any new drug against 
tuberculosis is its affordability, thus, low cost of production, 
storage, and distribution are high on the drug research agenda. 
Fourth, since new antituberculosis drugs will need to be co-
administered with antiretroviral drugs, drug–drug interactions 
of such combinations need to be extensively tested. Likewise, 
it is desirable that new drugs be able to be administered orally 
and suitable for application once a day.
Among the new compounds potentially meeting these 
criteria is TMC-207, which acts by inhibiting adenosine 
triphosphate (ATP0 synthase).46 A high-throughput screen 
using Mycobacterium smegmatis led to the discovery of 
TMC-207 and, together with rifapentine and pyrazinamide, it 
was effective in a mouse model of tuberculosis. First clinical 
assessment in placebo-controlled double-blind randomized 
trials showed promising results, verifying ATP synthase as a 
potential drug target.44 When added to standard therapy for 
MDR tuberculosis, TMC-207 reduced the time to conversion 
to a negative sputum culture.47
In addition, PNU-100480, an analog of the oxazolidinone 
linezolid, and SQ-109, a derivative of the ethylenediamine 
ethambutol, showed efficacy in a mouse model of tubercu-
losis when substituted for standard regimen components.48,49 
Both compounds have entered clinical trials and their assess-
ment is in progress.50
Finally, two members of the nitroimidazole family, OPC-
67683 and PA-824, are being assessed in clinical trials.51 Like 
all nitroimidazoles, their bactericidal function is believed to 
stem from reactive species generated through bioreductive 
activity.52 Early results suggest that the maximum potency 
of these substances can be achieved with doses of as little 
as 200 mg per day.44
This overview of some new drug candidates is by no 
means comprehensive, but gives an insight into current hopes 
and obstacles in the development of new antituberculosis 
treatments. With the drug candidates described, the end of 
the pipeline is still far from being reached. Instead, ongoing 
basic research is needed to identify drug combinations that 
prevent the rapid development of multidrug resistance, to 
develop easier forms of application, and to gain knowledge 
about potential drug–drug interactions. Ideally, a combina-
tion of drugs would act in a potent, synergistic manner, 
target multiple structures to circumvent the generation of 
drug-resistant strains, and avoid complications with co-
administered antiretroviral drugs. To achieve this goal, 
not only is progress in basic research needed but also clear 
guidelines for the development of new regimens. Owners of 
the individual drugs will also need to cooperate and allow 
combinations of compounds to be tested and refined.
vaccine development
While advances in the treatment of tuberculosis are undoubt-
edly necessary to reduce global disease burden, the   ultimate 
goal must be to achieve effective prevention through 
sterile eradication, that is, the complete elimination of 
M.   tuberculosis from the host after infection. The only means 
to achieve this aim is through the development of an effective 
vaccine.53 The current vaccine for tuberculosis, BCG, has 
quite an impressive record with respect to its safety and low 
cost. BCG has been used in more than 4 billion individuals 
over the last decades and protects against severe childhood 
tuberculosis. However, for various reasons, the vaccine fails 
to satisfactorily prevent adult pulmonary disease, and is 
therefore not sufficient to combat the epidemic.54
Table 1 Potential candidates for new antituberculosis drugs
Drug candidate Mechanism Attributes
TMC-207 Targeting of ATP synthase Efficacy proven in animal model and clinical trial; 
novel pharmaceutical target
PNU-100480 Linezolid-analog, targeting ribosome Novel pharmaceutical target
SQ-109 Ethambutol-analogue, targeting cell-wall synthesis Efficacy proven in animal model
OPC-67683 and PA-824 Prodrug; bioreactive activation Potentially effective against latent tuberculosis
Abbreviation: ATP, adenosine triphosphate.
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In principle, one has to distinguish two general approaches 
toward vaccination strategies against   tuberculosis.   Pre-  exposure 
vaccination aims at preventing disease in   individuals who 
have not yet encountered the pathogen M. tuberculosis. In 
contrast, postexposure vaccination tries to inhibit disease 
outbreak in people who are already infected. Although an 
estimated 2 billion humans harbor the pathogen, 90% of 
whom are not developing active disease, the former category 
is the one that most novel vaccine candidates belong to. So 
far, effective vaccine development has been hampered by the 
lack of reliable biomarkers to efficiently distinguish between 
noninfected individuals, latently infected subjects, and patients 
with active disease.55 Furthermore, despite recent progress in 
basic research, an optimal animal model to study the efficacy 
of novel vaccine candidates in vivo is still lacking.
There are several categories of new vaccine   candidates.56 
The first builds on the safety and efficacy of BCG. 
  Recombinant BCG strains have been optimized with respect 
to their immunogenicity and the expression of immu-
nodominant M. tuberculosis antigens.57 The second group 
can be used for boosting strategies, subsequent to BCG or 
a recombinant BCG. The rationale behind this group is to 
deliver antigens with an immunodominant effect, or antigens 
associated with dormancy, in an immunostimulatory context. 
This immunostimulation can be achieved either through viral 
vectors or through the combination with adjuvants.58 Finally, 
two candidates can be described as “therapeutic vaccines” 
and comprise whole attenuated mycobacteria. The vaccine 
candidates that are currently in clinical trials are described 
in detail in Table 2.
What does a possible scenario for the application of these 
new vaccine candidates look like? Optimally, future vaccina-
tions may consist of several coordinated steps. During early 
infancy, a highly efficient BCG replacement will be given 
as a primer. In later infancy, booster vaccines, which, in the 
best case, include several antigens from different stages of 
the mycobacterial life cycle, will be administered. These 
boosters will conceivably be given either as protein/adjuvant 
formulations or in the form of viral vectors – whichever 
proves more efficient and safe. In infants, booster vaccines 
should optimally consist of a large antigenic spectrum of 
metabolically active M. tuberculosis. However, it might be 
effective to include dormancy antigens in vaccine formula-
tions administered to adults. Together, these heterologous 
prime-boost strategies will potentially prove far superior in 
comparison with the current BCG vaccine.59
Conclusion
Tuberculosis is still a major cause of death worldwide and a 
central problem for global health. The disease, although both 
preventable and treatable in principle, has been neglected for 
decades and, thus, both research and disease management 
progress has stagnated for far too long. In the last decade, 
however, the first steps have been made to improve the 
Table 2 Pipeline of vaccine candidates that are currently in clinical trials
Category Vaccine candidate Mechanism Clinical trial
Live vaccines as BCG replacement AERAS-422 Expression of perfringolysin O to allow escape  
into the cytoplasm
Phase 1
Expression of immunodominant antigens  
85A, 85B and Rv3407
rBCGΔureC:Hly Listeriolysin enables BCG to escape from the  
endosome to enhance antigen cross-presentation
Phase 1 
completed
UreaseC-deficiency ensures optimal pH  
for listeriolysin activity
Subunit vaccines as BCG boost: viral vectors Ad5Ag85A Adenovirus type 5 expressing mycobacterial antigen 85A Phase 1
AERAS-402 Adenovirus type 35 expressing 85A, 85B and  
TB10.4 as a fusion protein
Phase 11
MvA85A Modified vaccinia virus Ankara expressing antigen 85A Phase 11b
Subunit vaccines as BCG boost:  
protein/adjuvant formulations
Hyvac4 Fusion protein of TB10.4 with antigen 85B plus  
adjuvant MPL or IC31
Phase 1
Hybrid 1 Fusion protein of ESAT-6 with antigen 85B plus  
adjuvant CAF01 or IC31
Phase 1
M72 Fusion protein of Mtb32 and Mt39 plus adjuvant AS02A Phase 11a 
completed
Therapeutic vaccines Mycobacterium vaccae Whole-cell vaccine (inactivated) Phase 1
RUTI® Detoxified liposomal cellular fragments  
of M. tuberculosis
Phase 1 
completed
Abbreviation: BCG, Bacille Calmette-Guérin.
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prevention, detection, and treatment of tuberculosis, not 
only in the economically developed world, but also with an 
increasing focus on poor countries.8 To initiate this devel-
opment, a paradigm shift was necessary. First, there is an 
increasing awareness that tuberculosis is not a conquered 
disease; rather, the disease is a larger global health problem 
today than ever before. Second, tuberculosis is a major 
roadblock to economic development in poor countries, and 
lack of economic development impedes the epidemiological 
control of tuberculosis. This vicious circle at the intersection 
of tuberculosis and poverty needs to be broken to provide 
sustained progress in the management of the disease. Third, 
tuberculosis is no longer considered solely a public health 
problem. Instead, the problem needs to be tackled as a wider 
development issue, including in terms of education, hygiene, 
public policy, housing, and social development.
The way to achieve this goal is through fostering public–
private partnerships. Incentives must be created for infectious 
disease researchers, pharmaceutical companies, and global 
heath institutions to work together with the aim of initiating 
the next steps toward reaching the United Nations Millennium 
Development Goal number 6,26 which includes reducing the 
global burden of tuberculosis.
As summarized in this review, many challenges remain. 
Defining clear biomarkers for tuberculosis diagnosis, remov-
ing financial barriers to treatment, and testing safety and 
efficacy of novel vaccine and drug candidates will be some 
of the most pressing goals to achieve in the near future.60 
  Nonetheless, the developments of the last decade, as exempli-
fied in this review, and new partnerships to fight this ancient 
disease have opened new avenues to reach the goal of reduc-
ing global tuberculosis burden in the coming years. There 
is hardly any other field of biomedical research and disease 
management that can foster global socioeconomic develop-
ment as much as the current fight against tuberculosis.
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